Prostate Cancer Progression and Risk Stratification

The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy after prior treatment, based on SECuRE trial data.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

CTCm from circulating tumor cells correlated with outcomes in mCRPC patients treated with bavdegalutamide in the ARDENT trial.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

Darolutamide plus ADT improved outcomes in metastatic hormone-sensitive prostate cancer, regardless of disease volume, in the phase 3 ARANOTE trial.